Benoit Chardon - 01 Aug 2023 Form 3 Insider Report for ALLURION TECHNOLOGIES, INC. (ALUR)

Role: Chief Commercial Officer
Signature: /s/ Jennifer Ausrotas, attorney-in-fact
Issuer symbol: ALUR
Transactions as of: 01 Aug 2023
Net transactions value: $0
Form type: 3
Filing time: 01 Aug 2023, 20:55:08 UTC
Next filing: 14 Dec 2023
SEC: View on sec.gov

Key filing fact

Benoit Chardon filed Form 3 for ALLURION TECHNOLOGIES, INC. (ALUR) on 01 Aug 2023.

Key facts

This page summarizes Benoit Chardon's Form 3 filing for ALLURION TECHNOLOGIES, INC. (ALUR).
0 reported transactions and 5 derivative rows are listed below.
Filing timestamp: 01 Aug 2023, 20:55.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC Source

Ownership activity is grounded in SEC Form 3 disclosures.

See Original Filing

Transactions Table

ALUR holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 33,644
Date: 01 Aug 2023
Ownership: Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

ALUR holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 01 Aug 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 97,799
Exercise price: $1.13
Footnotes: F1

ALUR holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 01 Aug 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 24,449
Exercise price: $1.17
Footnotes: F2

ALUR holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 01 Aug 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 29,339
Exercise price: $0.9500
Footnotes: F3

ALUR holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 01 Aug 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 24,449
Exercise price: $1.88
Footnotes: F4

ALUR holding Derivative

Contingency Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 01 Aug 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 48,133
Exercise price
Footnotes: F5, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option is fully vested.
F2	This option shall vest and become exercisable in monthly installments over a period of 48 months from January 1, 2020, subject to the Reporting Person's continued service on each such vesting date.
F3	25% of the shares underlying this option vested on July 1, 2021, and the remainder vests in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F4	25% of the shares underlying this option vested on January 1, 2023, and the remainder vests in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F5	Subject to the terms and conditions pursuant to that certain Business Combination Agreement ("BCA") dated as of February 9, 2023, as amended on May 2, 2023, by and among Compute Health Acquisition Corp., Compute Health Corp., Compute Health LLC, the Issuer (fka Allurion Technologies Holdings, Inc.), and Allurion Technologies, Inc. ("Private Allurion"), the contingent right to receive shares of Common Stock ("Contingency Shares"), was issued as follows: one-half of the Contingency Shares, in the aggregate, if, from the period beginning on the date on which the Issuer's registration statement on Form S-1 with respect to the resale of any Common Stock issued pursuant to the PIPE Financing is declared effective by the SEC until the date which is five calendar years after the Closing Date ("Earnout Period"),
F6	(Continued from footnote 5) the VWAP is greater than or equal to $15.00 over any 20 trading days within any consecutive 30 trading day period ("First Share Target"); and one-half of the Contingency Shares, in the aggregate, if, during the Earnout Period, the VWAP is greater than or equal to $20.00 over any 20 trading days within any consecutive 30 trading day period ("Second Share Target").

Remarks:

Exhibit 24 - Power of Attorney